Griseofulvin and terbinafine are considered effective first‐line therapies for tinea capitis (TC). Haematological dyscrasias and hepatic injury are possible adverse effects with both drugs. There is a debate in the literature regarding the necessity of laboratory monitoring during griseofulvin and terbinafine treatment. We aimed at assessing the prevalence and severity of haematological and hepatic laboratory test abnormalities in a paediatric cohort of African immigrants in Tel‐Aviv with TC who were treated with Terbinafine or Griseofulvin. We conducted a retrospective study of all TC cases diagnosed and treated at the paediatric dermatology clinic, Tel‐Aviv Medical centre, between June 2013 and March 2019. Epidemiologic, clinical and laboratory data were collected. Our cohort included 321 patients of whom 225 (70%) were treated with Griseofulvin and 96 (30%) with Terbinafine. We identified a total of 64 (20%) patients with haematological or hepatic laboratory test abnormalities that in most cases (96.3%) were considered as mild. No difference in laboratory abnormalities prevalence was identified between the griseofulvin and terbinafine groups (21.3% and 16.6%, respectively). Only one patient treated with Griseofulvin revealed significantly increased levels of hepatic aminotransferases that required discontinuation of treatment. Mild elevation in hepatic transaminases is relatively common among paediatric patients treated with systemic antifungal treatment for TC. However, significant laboratory abnormalities are extremely rare and may be diagnosed and addressed early through periodic laboratory tests monitoring.

中文翻译：

---

小儿头癣抗真菌治疗期间的实验室监测

灰黄霉素和特比萘芬被认为是治疗头癣（TC）的有效一线药物。血液恶液质和肝损伤是两种药物可能的不良反应。关于灰黄霉素和特比萘芬治疗期间实验室监测的必要性，文献中存在争议。我们旨在评估特拉维夫非洲移民儿童队列中接受特比萘芬或灰黄霉素治疗的 TC 儿童队列中血液学和肝脏实验室检查异常的患病率和严重程度。我们对 2013 年 6 月至 2019 年 3 月期间在特拉维夫医学中心儿科皮肤科诊所诊断和治疗的所有 TC 病例进行了回顾性研究。收集了流行病学、临床和实验室数据。我们的队列包括 321 名患者，其中 225 名 (70%) 接受灰黄霉素治疗，96 名 (30%) 接受特比萘芬治疗。我们确定了总共 64 (20%) 名血液或肝脏实验室检查异常的患者，在大多数情况下 (96.3%) 被认为是轻度的。灰黄霉素组和特比萘芬组之间的实验室异常发生率没有差异（分别为 21.3% 和 16.6%）。只有一名接受灰黄霉素治疗的患者发现肝转氨酶水平显着升高，需要停止治疗。在接受全身抗真菌治疗的儿科患者中，肝转氨酶轻度升高相对常见。然而，